As cancer treatments become more precise, the practice of cancer medicine becomes increasingly dependent on fundamental cancer research, as does the regulatory landscape for approval of drugs the patients receive. This year, the program committee has made special efforts to highlight all aspects of cancer research from concept to clinic. The AACR Annual Meeting 2012 has an extraordinary array of sessions that feature translational and clinical research, including clinical trials.
In addition to the presentation of a clinical trial in the Opening Plenary Session, this year’s Annual Meeting features an unprecedented four Clinical Trials Sessions featuring four clinical trials each, with an in-depth discussion of the science behind the trial following every individual presentation.
The Clinical Trials Sessions are as follows:
With rapid advances in science and technology and new breakthroughs in personalized medicine, the U.S. Food and Drug Administration (FDA) and other regulatory agencies are being asked to tackle increasingly complex issues. New in 2012, the Regulatory Science and Policy Track brings together representatives from academia, industry and the FDA to discuss the major barriers to efficient translation of emerging cancer science.
Regulatory Science Sessions include:
Register for the AACR Annual Meeting 2012.